

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **ABATTIS BIOCEUTICALS CORP.** (the "Issuer").

Trading Symbol: **FLU**

Number of Outstanding Listed Securities: **32,084,094**

Date: **January 8, 2014**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

For the month of December 2013, the Issuer continued its negotiations towards securing a definitive agreement with Borderland Bio-Diesel Ltd. (dba Farm Genesis Group).

2. Provide a general overview and discussion of the activities of management.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

NA

Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

NA

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

NA.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

On December 13, 2013, the Company extended the expiry of 2,000,000 share purchase warrants from December 12, 2013 to December 12, 2014. The warrants are exercisable at \$0.13 per share, subject to the Company's closing price being \$0.20 per share or higher for 10 consecutive days.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provides details of the relationship.

7. Describe the acquisition of new customers or loss of customers.
N/A
8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
N/A
9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
N/A
10. Report on any labour disputes and resolutions of those disputes if applicable.
The former Corporate Secretary of the Company has filed a claim with Employment Standards Branch claiming holiday pay. The Company takes the position that the holiday pay being claimed is excessive, as time was taken. A hearing is scheduled for January 16 2014.
11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
The shares-for-debt-settlement agreed to on November 28, 2013 have been issued and the Company is working with the officer of the Company to document the balance of debt to prevent any default in monies or notes outstanding.
13. Provide details of any securities issued and options or warrants granted.
N/A
14. Provide details of any loans to or by Related Persons.
The CEO of the Issuer continued to advance funds on a short-term basis. The CFO also advanced funds on a short-term basis.
15. Provide details of any changes in directors, officers or committee members.
On December 3, 2013, Nick Brusatore resigned as a director of the Company.
16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
The trends and risks which are likely to impact the Issuer are discussed in the Issuer's audited financial statements and corresponding Managements' Discussion & Analysis for the year ended September 30, 2012, which are filed on SEDAR effective February 28, 2013.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **January 8, 2014**

Michael Withrow
Name of Director or Senior Officer

“Michael Withrow”
Signature

President & CEO
Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer		December 2013	YY/MM/DD
Abattis Bioceticals Corp.			2014/01/08
Issuer Address			
Suite 1000 – 355 Burrard Street			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 2G8		(604) 888-1519	(604) 538-6650
Contact Name		Contact Position	Contact Telephone No.
Mike Withrow		President, CEO & Director	(604) 538-6650
Contact Email Address		Web Site Address	
mike.withrow@abattis.com		www.abattis.com	